Claims for Patent: 7,425,573

Summary for Patent: 7,425,573

Title:	Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
Abstract:	Treating or preventing degeneration or destruction of articular cartilage and/or subchondral bone in the affected joint of a mammal is accomplished by administering a compound of formula (I), wherein the variables have the meanings given in the present description. A preferred compound of formula (I) is formula (II). This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration ##STR00001##
Inventor(s):	Pelletier; Jean-Pierre (St. Lambert, CA), Martel-Pelletier; Johanne (St. Lambert, CA)
Assignee:	Merckle GmbH (Blaubeuren, DE) Ascentia Pharma Inc. (Montreal, CA)
Application Number:	10/486,912
Patent Claims:	1. A method for ameliorating degeneration or destruction in articular cartilage and/or subchondral bone prior to the development of manifest osteoarthritis, comprising administering to a mammal in need thereof a chondroprotective amount of [6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-9H-pyrrolizine-5-yl- ]-acetic acid of the formula (Ia): ##STR00006## a physiologically acceptable salt or a physiologically hydrolysable ester thereof. 2. The method according to claim 1, which ameliorates degeneration of articular cartilage. 3. The method according to claim 1, which ameliorates destruction of articular cartilage. 4. The method according to claim 1, wherein said mammal is human. 5. The method according to claim 1, wherein said mammal is a cat or dog. 6. The method according to claim 1, wherein said mammal is a horse. 7. The method according to claim 1, which ameliorates injury, damage or loss of articular cartilage. 8. The method according to claim 1, which ameliorates injury, damage or loss of subchondral bone. 9. The method according to claim 1, wherein injury and loss of articular cartilage is asymptomatic. 10. The method according to claim 1, wherein said degeneration or destruction is determined by one or more positive results from a biochemical test performed on body fluids or joint tissue of a mammal with respect to one or more of the following substances: (1) increased interleukin-1 beta (IL-.beta.); (2) increased tumor necrosis factor alpha (TNF.alpha.); (3) increased ratio of IL-1.beta. to IL-1 receptor antagonist protein (IL-1 Ra); (4) increased expression of p55 TNF receptors (p55 TNF-R); (5) increased interleukin-6 (IL-6); increased leukemia inhibitory factor (LIF); (6) unchanged or decreased insulin-like growth factor-1 (IGF-1); (7) decreased transforming growth factor beta (TGF.beta.); unchanged or decreased platelet-derived growth factor (PDGF); and (8) unchanged or decreased basic fibroblast growth factor (b-FGF). 11. The method according to claim 1, wherein said degeneration or destruction is determined by one or more positive results from a biochemical test performed on body fluids or joint tissue of a mammal with respect to one or more of the following substances: (9) increased keratin sulfate; (10) increased matrix metalloproteases (MMPs) including stromelysin; (11) increased ratio of matrix metalloproteases (MMPs) including stromelysin, to tissue inhibitor of metalloproteases (TIMP); (12) increased osteocalcin; (13) increased alkaline phosphatase; (14) increased cAMP responsive to hormone challenge; (15) increased urokinase plasminogen activator (uPA); (16) increased cartilage oligomeric matrix protein; (17) presence of type-II specific collagen neoepitopes and (18) increased collagenase. 12. The method according to claim 1, wherein said compound of formula (Ia) is administered in an amount of 0.5-10 mg/kg/day. 13. The method according to claim 1, which includes administering in addition to the compound of formula (Ia), the salt or the ester thereof, one or more members selected from the group consisting of polysulfated glycosaminoglycan (PSGAG), glucosamine, chondroitin sulfate (CS), hyaluronic acid (HA), and pentosan polysulfate (PPS). 14. The method according to claim 1, which includes administering in addition to the compound of formula (Ia), the salt or the ester thereof, one or more members selected from the group consisting of doxycycline and minocycline. 15. The method according to claim 1, which includes administering in addition to the compound of formula (Ia), the salt or the ester thereof, one or more antibiotics, antifungal, antiprotozoal, or antiviral agent(s). 16. The method according to claim 1, which includes administering in addition to the compound of formula (Ia), the salt or the ester thereof one or more NSAIDs. 17. The method according to claim 1, which includes administering in addition to the compound of formula (Ia), the salt or the ester thereof, one or more inhibitors of mediators of inflammation. 18. The method according to claim 1, wherein said compound of formula (Ia), its salt or ester, is locally injected, infused, implanted, deposited, inserted, or instilled. 19. The method according to claim 1, wherein said compound of formula (Ia), its salt or ester, is administered in a delayed-release, extended-release, sustained-release, or controlled-release form in combination with a bioerodable polymer.

Details for Patent 7,425,573

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2021-08-30
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2021-08-30